

A clinical briefing for providers on the Macrodantin (Nitrofurantoin) supply situation in 2026 — shortage timeline, prescribing considerations, and patient tools.
Nitrofurantoin remains a first-line agent for uncomplicated urinary tract infections per IDSA guidelines, but supply disruptions continue to affect patient access. This briefing covers the current availability landscape, prescribing implications, and tools to help your patients locate their medication.
If your patients are reporting difficulty filling Nitrofurantoin prescriptions, they're not alone — and there are concrete steps both you and your patients can take to navigate the situation.
The Nitrofurantoin supply picture is nuanced and depends on formulation:
Nitrofurantoin oral suspension has been listed on the ASHP drug shortage database for several years, beginning around 2020. Key details:
Capsule formulations are not formally listed as in shortage by the FDA or ASHP. However:
Given the supply landscape, consider the following when prescribing Nitrofurantoin:
If Nitrofurantoin is unavailable in any form, evidence-based alternatives for uncomplicated UTI include:
Avoid empiric fluoroquinolones for uncomplicated cystitis given resistance concerns and FDA safety warnings.
Nitrofurantoin maintains exceptionally low resistance rates — only 3-4% of E. coli isolates show resistance, compared to >20% for TMP-SMX and fluoroquinolones. This makes the supply situation particularly frustrating from a stewardship perspective. Switching patients to broader-spectrum agents when Nitrofurantoin is unavailable carries antibiotic resistance implications worth noting.
Help your patients navigate availability with these practical strategies:
Even when Nitrofurantoin is available, cost can be a barrier for uninsured or underinsured patients:
Generic Nitrofurantoin is on most insurance formularies at Tier 1 or Tier 2. Brand-name Macrodantin may require Tier 3 copay or prior authorization.
The Nitrofurantoin oral suspension shortage is unlikely to resolve quickly given the limited manufacturer base and lack of timeline from Teva. Capsule availability should remain generally stable but with continued intermittent local disruptions.
From a stewardship perspective, maintaining access to Nitrofurantoin is important. Its narrow spectrum, low resistance rates, and strong evidence base make it an irreplaceable tool in the UTI treatment arsenal. Encouraging patients to use availability tools like Medfinder can reduce prescription abandonment and keep patients on first-line therapy.
The Macrodantin supply situation requires pragmatic clinical decision-making. Default to Macrobid or generic Nitrofurantoin mono/macro when possible for better availability and adherence. When switching to alternatives is necessary, match the agent to local resistance patterns and patient factors. And equip your patients with tools like Medfinder to help them find their medication.
Access Medfinder for Providers: medfinder.com/providers — Help your patients find Macrodantin and other medications in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.